NCT02780830View on ClinicalTrials.gov

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

June 30, 2016

Primary Completion Date

April 30, 2019

Study Completion Date

April 30, 2019

Conditions
Core: Relapsed or Refractory Diffuse Large B-Cell LymphomaModule 1: Non-GCB Diffuse Large B-Cell Lymphoma
Interventions
DRUG

AZD2014

AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.

DRUG

Ibrutinib

Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY